Zion Pharma

Executive Summary

Zion Pharma is a clinical-stage biotechnology company headquartered in Hong Kong with R&D operations in Shanghai and Suzhou, focused on developing innovative small molecule oncology drugs. Founded in 2018, the company leverages deep expertise in DMPK to design best-in-class and first-in-class therapeutics targeting significant unmet needs in cancer. With $40 million raised to date, Zion Pharma is advancing its pipeline through Phase 1 clinical trials, aiming to differentiate its candidates through superior pharmacokinetic and pharmacodynamic profiles. The company's approach addresses key challenges in oncology drug development, including resistance mechanisms and tumor heterogeneity. As a private, early-stage biotech, Zion Pharma's progress is closely watched by investors interested in precision oncology and small molecule innovation. Key upcoming catalysts include initial efficacy and safety data from ongoing Phase 1 studies, potential expansion into additional indications, and strategic partnership discussions to support further development.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 dose expansion data for lead candidate40% success
• Q4 2026IND filing for second pipeline asset50% success
• Q4 2026Potential licensing or collaboration deal30% success